ArticleDrug design, development and therapy2024
Evaluating the Efficacy of Oral Ivermectin on Clinical Symptoms and
Article in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- It Mite Not Be Graft-Versus-Host Disease: Frequency and Clinical Features of Demodex Folliculitis After Allogeneic Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2026Article
- Sebaceous gland necrosis induced by Demodex mites: a case report.JAAD case reports · 2026Article
- Efficacy of topical Ivermectin in controlling humanParasite epidemiology and control · 2025Article
- Article
- Is systemic ivermectin as effective as topical ivermectin in eliminating Demodex mites?Archives of dermatological research · 2025Article
- Reducing ocularFrontiers in allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatologists consistently face challenges in treating demodicosis due to its high recurrence rate and difficulty normalizing the Purpose: This study aims to evaluate the effectiveness of oral ivermectin on clinical symptoms and Dds of patients with demodicosis. Methods: This prospective, quasi-experimental study included 40 demodicosis patients (20 with Results: In our study, 75% of patients achieved clinical remission, showing excellent clinical improvement with Dds ≤ 5 D/cm Conclusion: Oral ivermectin effectively improves clinical symptoms and normalizes Dds in patients with demodicosis. Patients with higher Dds require a longer treatment than those with lower Dds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.